A Safety and Efficacy Study of Enzalutamide in Indian Patients With Progressive Metastatic Castration-Resistant Prostate Cancer (mCRPC) Previously Treated With Docetaxel-Based Chemotherapy

Inclusion Criteria:

1. Subject is diagnosed with histologically or cytologically confirmed adenocarcinoma of the prostate without neuroendocrine differentiation, signet cell or small cell histology.
2. Subject with established diagnosis of metastatic castration-resistant prostate carcinoma.
3. Subject is being newly initiated on Xtandi treatment (Enzalutamide).
4. Subject has an estimated life expectancy of ≥ 6 months.
5. Subject agrees not to participate in another interventional study while participating in the present study.

Exclusion Criteria:

1. Subject who is not eligible to receive Xtandi as per the locally approved prescribing information.
2. Subject participating or planning to participate in any interventional drug trial during the course of this trial.
3. Subject has received investigational study within 28 days or 5 half-lives, whichever is longer, prior to screening.
4. Subject has any condition which makes the subject unsuitable for study participation.